-
1
-
-
0029882358
-
Recent progress in advanced glycation and diabetic vascular disease: Role of advanced glycation end product receptors
-
H. Vlassara, and R. Bucala Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors Diabetes Suppl 3 1996 S65 S66
-
(1996)
Diabetes Suppl
, vol.3
-
-
Vlassara, H.1
Bucala, R.2
-
2
-
-
0023950461
-
Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
-
M. Brownlee, A. Cerami, and H. Vlassara Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications N Engl J Med 318 1998 1315 1321
-
(1998)
N Engl J Med
, vol.318
, pp. 1315-1321
-
-
Brownlee, M.1
Cerami, A.2
Vlassara, H.3
-
3
-
-
21044443182
-
Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy
-
DOI 10.2174/1381612054367300
-
S. Yamagishi, and T. Imaizumi Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy Curr Pharm Des 11 2005 2279 2299 (Pubitemid 40872698)
-
(2005)
Current Pharmaceutical Design
, vol.11
, Issue.18
, pp. 2279-2299
-
-
Yamagishi, S.-I.1
Imaizumi, T.2
-
4
-
-
0142089894
-
Blockade of receptor for advanced glycation endproducts: A new target for therapeutic intervention in diabetic complications and inflammatory disorders
-
DOI 10.1016/j.abb.2003.08.030
-
B.I. Hudson, L.G. Bucciarelli, and T. Wendt Blockade of receptor for advanced glycation end products: a new target for therapeutic intervention in diabetic complications and inflammatory disorders Arch Biochem Biophys 419 2003 80 88 (Pubitemid 37272161)
-
(2003)
Archives of Biochemistry and Biophysics
, vol.419
, Issue.1
, pp. 80-88
-
-
Hudson, B.I.1
Bucciarelli, L.G.2
Wendt, T.3
Sakaguchi, T.4
Lalla, E.5
Qu, W.6
Lu, Y.7
Lee, L.8
Stern, D.M.9
Naka, Y.10
Ramasamy, R.11
Yan, S.D.12
Yan, S.F.13
D'Agati, V.14
Schmidt, A.M.15
-
5
-
-
35348927441
-
Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation and products (sRAGE) in diabetes
-
DOI 10.2174/138945007782151298
-
S. Yamagishi, T. Matsui, and K. Nakamura Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes Curr Drug Targets 8 2007 1138 1143 (Pubitemid 47578142)
-
(2007)
Current Drug Targets
, vol.8
, Issue.10
, pp. 1138-1143
-
-
Yamagishi, S.-I.1
Matsui, T.2
Nakamura, K.3
-
6
-
-
0037377697
-
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy
-
T.M. Wendt, N. Tanji, and J. Guo RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy Am J Pathol 162 2003 1123 1137 (Pubitemid 36350658)
-
(2003)
American Journal of Pathology
, vol.162
, Issue.4
, pp. 1123-1137
-
-
Wendt, T.M.1
Tanji, N.2
Guo, J.3
Kislinger, T.R.4
Qu, W.5
Lu, Y.6
Bucciarelli, L.G.7
Ling Rong, L.8
Moser, B.9
Markowitz, G.S.10
Stein, G.11
Bierhaus, A.12
Liliensiek, B.13
Arnold, B.14
Nawroth, P.P.15
Stern, D.M.16
D'Agati, V.D.17
Schmidt, A.M.18
-
7
-
-
0034947508
-
Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice
-
DOI 10.1172/JCI200111771
-
Y. Yamamoto, I. Kato, and T. Doi Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice J Clin Invest 108 2001 261 268 (Pubitemid 32656250)
-
(2001)
Journal of Clinical Investigation
, vol.108
, Issue.2
, pp. 261-268
-
-
Yamamoto, Y.1
Kato, I.2
Doi, T.3
Yonekura, H.4
Ohashi, S.5
Takeuchi, M.6
Watanabe, T.7
Yamagishi, S.-I.8
Sakurai, S.9
Takasawa, S.10
Okamoto, H.11
Yamamoto, H.12
-
8
-
-
77955414324
-
Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation
-
Y. Ide, T. Matsui, Y. Ishibashi, M. Takeuchi, and S. Yamagishi Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation Microvasc Res 80 2010 227 232
-
(2010)
Microvasc Res
, vol.80
, pp. 227-232
-
-
Ide, Y.1
Matsui, T.2
Ishibashi, Y.3
Takeuchi, M.4
Yamagishi, S.5
-
9
-
-
58149090676
-
The role of incretins in glucose homeostasis and diabetes treatment
-
W. Kim, and J.M. Egan The role of incretins in glucose homeostasis and diabetes treatment Pharmacol Rev 60 2008 470 512
-
(2008)
Pharmacol Rev
, vol.60
, pp. 470-512
-
-
Kim, W.1
Egan, J.M.2
-
10
-
-
36148996843
-
G-protein-coupled receptors and islet function-Implications for treatment of type 2 diabetes
-
DOI 10.1016/j.pharmthera.2007.08.002, PII S0163725807001593
-
M.S. Winzell, and B. Ahrén G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes Pharmacol Rev 116 2007 437 448 (Pubitemid 350116941)
-
(2007)
Pharmacology and Therapeutics
, vol.116
, Issue.3
, pp. 437-448
-
-
Winzell, M.S.1
Ahren, B.2
-
11
-
-
38849195749
-
Glucagon-like peptide-1 attenuates tumour necrosis factor-"-mediated induction of plasmogen activator inhibitor-1 expression
-
DOI 10.1677/JOE-07-0387
-
H. Liu, Y. Hu, R.W. Simpson, and A.E. Dear Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasmogen activator inhibitor-1 expression J Endocrinol 196 2008 57 65 (Pubitemid 351234571)
-
(2008)
Journal of Endocrinology
, vol.196
, Issue.1
, pp. 57-65
-
-
Liu, H.1
Hu, Y.2
Simpson, R.W.3
Dear, A.E.4
-
12
-
-
73949118948
-
Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression
-
Y. Ishibashi, T. Matsui, M. Takeuchi, and S. Yamagishi Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression Biochem Biophys Res Commun 391 2010 1405 1408
-
(2010)
Biochem Biophys Res Commun
, vol.391
, pp. 1405-1408
-
-
Ishibashi, Y.1
Matsui, T.2
Takeuchi, M.3
Yamagishi, S.4
-
13
-
-
67650057935
-
A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules
-
H. Liu, A.E. Dear, L.B. Knudsen, and R.W. Simpson A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules J Endocrinol 201 2009 59 66
-
(2009)
J Endocrinol
, vol.201
, pp. 59-66
-
-
Liu, H.1
Dear, A.E.2
Knudsen, L.B.3
Simpson, R.W.4
-
14
-
-
33750913676
-
Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation
-
DOI 10.1007/s00125-006-0437-7
-
T. Yoshida, S. Yamagishi, and K. Nakamura Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation Diabetologia 49 2006 3094 3099 (Pubitemid 44730314)
-
(2006)
Diabetologia
, vol.49
, Issue.12
, pp. 3094-3099
-
-
Yoshida, T.1
Yamagishi, S.2
Nakamura, K.3
Matsui, T.4
Imaizumi, T.5
Takeuchi, M.6
Koga, H.7
Ueno, T.8
Sata, M.9
-
15
-
-
0033304603
-
The glucagon-like peptides
-
T.J. Kieffer, and J.F. Habener The glucagon-like peptides Endocr Rev 20 1999 876 913 (Pubitemid 30647076)
-
(1999)
Endocrine Reviews
, vol.20
, Issue.6
, pp. 876-913
-
-
Kieffer, T.J.1
Habener, J.F.2
-
16
-
-
33947580463
-
Nifedipine, a calcium-channel blocker, inhibits advanced glycation end-product-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells
-
T. Matsui, S. Yamagishi, K. Nakamura, M. Takeuchi, and H. Inoue Nifedipine, a calcium-channel blocker, inhibits advanced glycation end-product-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells J Int Med Res 35 2007 107 112 (Pubitemid 46477534)
-
(2007)
Journal of International Medical Research
, vol.35
, Issue.1
, pp. 107-112
-
-
Matsui, T.1
Yamagishi, S.2
Nakamura, K.3
Inoue, H.4
Takeuchi, M.5
-
17
-
-
0031773362
-
Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells
-
DOI 10.1007/s001250051089
-
S. Yamagishi, H. Fujimori, H. Yonekura, Y. Yamamoto, and H. Yamamoto Advanced glycation end products inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells Diabetologia 41 1998 1435 1441 (Pubitemid 28551614)
-
(1998)
Diabetologia
, vol.41
, Issue.12
, pp. 1435-1441
-
-
Yamagishi, S.1
Fujimori, H.2
Yonekura, H.3
Yamamoto, Y.4
Yamamoto, H.5
-
18
-
-
0036765450
-
2 analogue, protects against advanced glycation end products-induced injury in cultured retinal pericytes
-
S. Yamagishi, S. Amano, Y. Inagaki, T. Okamoto, M. Takeuchi, and Z. Makita Beraprost sodium, a prostaglandin I2 analogue, protects against advanced glycation end products-induced injury in cultured retinal pericytes Mol Med 8 2002 546 550 (Pubitemid 36332366)
-
(2002)
Molecular Medicine
, vol.8
, Issue.9
, pp. 546-550
-
-
Yamagishi, S.-I.1
Amano, S.2
Inagaki, Y.3
Okamoto, T.4
Takeuchi, M.5
Makita, Z.6
-
19
-
-
0037036345
-
Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells
-
DOI 10.1074/jbc.M202634200
-
S. Yamagishi, Y. Inagaki, and T. Okamoto Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells J Biol Chem 277 2002 20309 20315 (Pubitemid 34967325)
-
(2002)
Journal of Biological Chemistry
, vol.277
, Issue.23
, pp. 20309-20315
-
-
Yamagishi, S.-I.1
Inagaki, Y.2
Okamoto, T.3
Amano, S.4
Koga, K.5
Takeuchi, M.6
Makita, Z.7
-
20
-
-
0033865561
-
Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy
-
DOI 10.1046/j.1523-1755.2000.00214.x
-
N. Banba, T. Nakamura, and M. Matsumura Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy Kidney Int 58 2000 684 690 (Pubitemid 30620017)
-
(2000)
Kidney International
, vol.58
, Issue.2
, pp. 684-690
-
-
Banba, N.1
Nakamura, T.2
Matsumura, M.3
Kuroda, H.4
Hattori, Y.5
Kasai, K.6
-
21
-
-
0036781581
-
Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes
-
DOI 10.2337/diacare.25.10.1829
-
F. Chiarelli, F. Cipollone, and A. Mohn Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes Diabetes Care 25 2002 1829 1834 (Pubitemid 41071095)
-
(2002)
Diabetes Care
, vol.25
, Issue.10
, pp. 1829-1834
-
-
Chiarelli, F.1
Cipollone, F.2
Mohn, A.3
Marini, M.4
Iezzi, A.5
Fazia, M.6
Tumini, S.7
De Cesare, D.8
Pomilio, M.9
Pierdomenico, S.D.10
Di Gioacchino, M.11
Cuccurullo, F.12
Mezzetti, A.13
-
22
-
-
30944456936
-
Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice
-
DOI 10.1038/sj.ki.5000014, PII 5000014
-
F.Y. Chow, D.J. Nikolic-Paterson, and E. Ozols Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice Kidney Int 69 2006 73 80 (Pubitemid 43117741)
-
(2006)
Kidney International
, vol.69
, Issue.1
, pp. 73-80
-
-
Chow, F.Y.1
Nikolic-Paterson, D.J.2
Ozols, E.3
Atkins, R.C.4
Rollin, B.J.5
Tesch, G.H.6
-
23
-
-
60549097258
-
Targeting incretins in type 2 diabetes: Role of GLP-1 receptor agonists and DPP-4 inhibitors
-
R.E. Pratley, and M. Gilbert Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors Rev Diabet Stud 5 2008 73 94
-
(2008)
Rev Diabet Stud
, vol.5
, pp. 73-94
-
-
Pratley, R.E.1
Gilbert, M.2
-
24
-
-
33749871472
-
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
-
DOI 10.1210/jc.2006-1009
-
G.A. Herman, A. Bergman, and C. Stevens Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes J Clin Endocrinol Metab 91 2006 4612 4619 (Pubitemid 44833446)
-
(2006)
Journal of Clinical Endocrinology and Metabolism
, vol.91
, Issue.11
, pp. 4612-4619
-
-
Herman, G.A.1
Bergman, A.2
Stevens, C.3
Kotey, P.4
Yi, B.5
Zhao, P.6
Dietrich, B.7
Golor, G.8
Schrodter, A.9
Keymeulen, B.10
Lasseter, K.C.11
Kipnes, M.S.12
Snyder, K.13
Hilliard, D.14
Tanen, M.15
Cilissen, C.16
De Smet, M.17
De Lepeleire, I.18
Van Dyck, K.19
Wang, A.Q.20
Zeng, W.21
Davies, M.J.22
Tanaka, W.23
Holst, J.J.24
Deacon, C.F.25
Gottesdiener, K.M.26
Wagner, J.A.27
more..
-
25
-
-
77954798308
-
Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects
-
A. Sarashina, S. Sesoko, and M. Nakashima Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects Clin Ther 32 2010 1188 1204
-
(2010)
Clin Ther
, vol.32
, pp. 1188-1204
-
-
Sarashina, A.1
Sesoko, S.2
Nakashima, M.3
-
26
-
-
0036676385
-
Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects
-
DOI 10.2337/diacare.25.8.1398
-
B. Elbrønd, G. Jakobsen, and S. Larsen Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects Diabetes Care 25 2002 1398 1404 (Pubitemid 41071152)
-
(2002)
Diabetes Care
, vol.25
, Issue.8
, pp. 1398-1404
-
-
Elbrond, B.1
Jakobsen, G.2
Larsen, S.3
Agerso, H.4
Jensen, L.B.5
Rolan, P.6
Sturis, J.7
Hatorp, V.8
Zdravkovic, M.9
-
27
-
-
33746019939
-
Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression
-
DOI 10.1074/jbc.M602110200
-
S. Yamagishi, K. Nakamura, and T. Matsui Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression J Biol Chem 281 2006 20213 20220 (Pubitemid 44065796)
-
(2006)
Journal of Biological Chemistry
, vol.281
, Issue.29
, pp. 20213-20220
-
-
Yamagishi, S.-I.1
Nakamura, K.2
Matsui, T.3
Inagaki, Y.4
Takenaka, K.5
Jinnouchi, Y.6
Yoshida, Y.7
Matsuura, T.8
Narama, I.9
Motomiya, Y.10
Takeuchi, M.11
Inoue, H.12
Yoshimura, A.13
Bucala, R.14
Imaizumi, T.15
-
28
-
-
0032810308
-
Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients
-
M. Takeuchi, Z. Makita, K. Yanagisawa, K. Kameda, and T. Koike Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients Mol Med 5 1999 393 405 (Pubitemid 29382313)
-
(1999)
Molecular Medicine
, vol.5
, Issue.6
, pp. 393-405
-
-
Takeuchi, M.1
Makita, Z.2
Yanagisawa, K.3
Kameda, Y.4
Koike, T.5
-
29
-
-
0035715943
-
Immunological detection of a novel advanced glycation end-product
-
M. Takeuchi, Y. Yanase, and N. Matsuura Immunological detection of a novel advanced glycation end-product Mol Med 7 2001 783 791 (Pubitemid 34175300)
-
(2001)
Molecular Medicine
, vol.7
, Issue.11
, pp. 783-791
-
-
Takeuchi, M.1
Yanase, Y.2
Matsuura, N.3
Yamagishi, S.-I.4
Kameda, Y.5
Bucala, R.6
Makita, Z.7
|